GRAL:NASDAQ
Grail Inc
$61.11
arrow_downward
-8.17%(-5.44) 1D
Jun 5, 10:54:30 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$63.99
High
$65.53
Low
$60.34
Mkt. cap
2.63B
Avg. vol.
768.89K
Volume
166.03K
52-wk high
$118.84
52-wk low
$29.95
EPS
-$10.37
Shares outstanding
42.92M
No. of employees
910
Open
$63.99
High
$65.53
Low
$60.34
Mkt. cap
2.63B
Avg. vol.
768.89K
Volume
166.03K
52-wk high
$118.84
52-wk low
$29.95
EPS
-$10.37
Shares outstanding
42.92M
No. of employees
910
Analyst outlook
Analyst Ratings
Based on 8 analysts giving stock ratings to GRAL in the past 3 months
Buy
Buy
4
Hold
4
Sell
0
12 month forecast
Based on 8 Wall Street analysts offering 12 month price targets for GRAL in the last 3 months.
Highest
Current $61.11
$80.00 (+30.91%)
Average
$66.50 (+8.82%)
Lowest
$56.00 (-8.36%)
News stories
From sources across the web
TipRanks
·
33 minutes ago
Why Are Grail Shares Sliding Despite New Coverage?
Yahoo Finance
·
3 hours ago
Here's Why Grail Stock Soared Higher in May (And Where the Company is Heading Now)
Investing.com
·
7 hours ago
Grail stock initiated at Neutral by Goldman Sachs on FDA uncertainty
Simply Wall Street
·
13 hours ago
Grail (GRAL) Valuation Check As ASCO 2026 Galleri Data Lifts Early Cancer Detection Story
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorBiotechnology
Websitegrail.com
AI content may include mistakes. Learn more